RCM
ASBPW

Radcliffe Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Radcliffe Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-163,800
Closed -$8.12K – 262
2023
Q3 		$8.12K Hold
163,800
– – ﹤0.01% 362
2023
Q2 		$9K Hold
163,800
– – ﹤0.01% 435
2023
Q1 		$7.37K Hold
163,800
– – ﹤0.01% 578
2022
Q4 		$1.69M Hold
163,800
– – 0.05% 527
2022
Q3 		$1.66M Buy
163,800
+13,800
+9% +$2.01K 0.04% 732
2022
Q2 		$1.5M Buy
+150,000
New +$32.6K 0.03% 805

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Radcliffe Capital Management's ASBPW Position: Q4 2023 in Review

Radcliffe Capital Management sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2023, closing a stake of 163,800 shares — an estimated $8.12K sold.

Radcliffe Capital Management first reported a position in ASBPW in Q2 2022 and held it in 6 quarters. The position peaked at $1.69M in Q4 2022. 35 funds tracked by Wall St. Rank hold ASBPW as of Q4 2023.

  • Radcliffe Capital Management reported no remaining Aspire Biopharma Warrant position as of Q4 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 163,800 Aspire Biopharma Warrant shares in Q4 2023, an estimated $8.12K.
  • Radcliffe Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 6 quarters.
  • Radcliffe Capital Management's Aspire Biopharma Warrant position peaked at $1.69M in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2023.

Based on Radcliffe Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.